Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu Nipocalimab bei Erwachsenen mit primärem Sjögren-Syndrom (pSS)

15. Oktober 2026 aktualisiert von: Janssen Research & Development, LLC

Eine randomisierte, placebokontrollierte, doppelblinde, multizentrische Studie zur Bewertung der Wirksamkeit und Sicherheit von Nipocalimab bei Erwachsenen mit primärem Sjögren-Syndrom (pSS)

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

163

Phase

  • Phase 2

Erweiterter Zugriff

Vorübergehend nicht verfügbar außerhalb der klinischen Studie. Siehe erweiterter Zugriffsdatensatz.

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Berlin, Deutschland, 10117
        • Charite Universitaetsmedizin Berlin
      • Cologne, Deutschland, 50923
        • Uniklinik Köln
      • Dresden, Deutschland, 01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Hamburg, Deutschland, 20095
        • Hamburger Rheuma Forschungszentrum II
      • Kirchheim unter Teck, Deutschland, 73230
        • medius KLINIK KIRCHHEIM
      • Tübingen, Deutschland, 72076
        • Universitatsklinikum Tubingen
      • La Tronche, Frankreich, 38700
        • CHU de Grenoble Hopital Albert Michallon
      • Le Mans, Frankreich, 72037
        • Centre Hospitalier Le Mans
      • Marseille, Frankreich, 13285
        • Hopital Saint Joseph
      • Paris, Frankreich, 75013
        • Hopital Pitie Salpetriere
      • Strasbourg, Frankreich, 67098
        • CHRU Hôpital de Hautepierre
      • Brescia, Italien, 25123
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
      • Catania, Italien, 95100
        • P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
      • Milan, Italien, 20132
        • IRCCS Ospedale San Raffaele
      • Palermo, Italien, 90129
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Verona, Italien, 37126
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Fuchū, Japan, 183 8524
        • Tokyo Metropolitan Tama Medical Center
      • Nagasaki, Japan, 852-8501
        • Nagasaki University Hospital
      • Sapporo, Japan, 060-8648
        • Hokkaido University Hospital
      • Tokyo, Japan, 104 8560
        • St. Luke's International Hospital
      • Tokyo, Japan, 173 8610
        • Nihon University Itabashi Hospital
      • Tsukuba, Japan, 305-8520
        • University of Tsukuba Hospital
      • Leeuwarden, Niederlande, 8934 AD
        • Medisch Centrum Leeuwarden
      • Rotterdam, Niederlande, 3015 GD
        • Erasmus Medisch Centrum
      • Bydgoszcz, Polen, 85-065
        • Nasz Lekarz Przychodnie Medyczne
      • Bydgoszcz, Polen, 85-168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
      • Gmina Końskie, Polen, 26 200
        • Zespolu Opieki Zdrowotnej w Konskich
      • Krakow, Polen, 30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Lublin, Polen, 20-607
        • REUMED Zespol Poradni Specjalistycznych Filia nr 2
      • Poznan, Polen, 61 113
        • Centrum Medyczne
      • Warsaw, Polen, 00-874
        • Medycyna Kliniczna
      • Warsaw, Polen, 02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw, Polen, 03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw, Polen, 52 415
        • Centrum Medyczne Oporow
      • Lisbon, Portugal, 1050-034
        • Instituto Portugues de Reumatologia
      • Ponte de Lima, Portugal, 4990-078
        • ULSAM, EPE - Hospital Conde de Bertiandos
      • A Coruña, Spanien, 15006
        • Hosp Univ A Coruna
      • Córdoba, Spanien, 14004
        • Hosp Reina Sofia
      • Mérida, Spanien, 6800
        • Hosp. de Merida
      • Sabadell, Spanien, 08208
        • Corporacio Sanitari Parc Tauli
      • Salamanca, Spanien, 37007
        • Hosp Clinico Univ de Salamanca
      • Seville, Spanien, 41010
        • Hosp. Infanta Luisa
      • Taipei, Taiwan, 11490
        • Tri-Service General Hospital
      • Taoyuan, Taiwan, 333
        • Chang Gung Memorial Hospital Linkou Branch
    • Alabama
      • Anniston, Alabama, Vereinigte Staaten, 36207
        • Anniston Medical Clinic
    • Arizona
      • Glendale, Arizona, Vereinigte Staaten, 85306
        • Arizona Arthritis and Rheumatology Research PLLC
      • Mesa, Arizona, Vereinigte Staaten, 85210
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Fullerton, California, Vereinigte Staaten, 92835
        • St. Jude Heritage Medical Group
      • Upland, California, Vereinigte Staaten, 91786
        • Inland Rheumatology Clinical Trials, Inc.
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80230
        • Denver Arthritis Clinic
      • Denver, Colorado, Vereinigte Staaten, 80228
        • Colorado Arthritis Associates
    • Florida
      • Boca Raton, Florida, Vereinigte Staaten, 33486
        • Rheumatology Associates Of South Florida
      • Brandon, Florida, Vereinigte Staaten, 33511
        • Bay Area Arthritis and Osteoporosis
      • Fort Lauderdale, Florida, Vereinigte Staaten, 33309
        • Centre for Rheumatology, Immunology and Arthritis
      • Jacksonville, Florida, Vereinigte Staaten, 32209
        • University of Florida Health Jacksonville
      • Orlando, Florida, Vereinigte Staaten, 32835
        • Omega Research Consultants
    • Illinois
      • Gurnee, Illinois, Vereinigte Staaten, 60031
        • Clinical Investigation Specialists
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66160
        • University of Kansas Medical Center
    • Minnesota
      • Eagan, Minnesota, Vereinigte Staaten, 55121
        • St. Paul Rheumatology P A
    • Mississippi
      • Tupelo, Mississippi, Vereinigte Staaten, 38801
        • North Mississippi Medical Clinics
    • North Carolina
      • Salisbury, North Carolina, Vereinigte Staaten, 28144
        • PMG Research of Salisbury
    • Pennsylvania
      • Duncansville, Pennsylvania, Vereinigte Staaten, 16635
        • Altoona Center For Clinical Research
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • University of Pennsylvania
    • South Carolina
      • Columbia, South Carolina, Vereinigte Staaten, 29204
        • Columbia Arthritis Center
    • Tennessee
      • Jackson, Tennessee, Vereinigte Staaten, 38305
        • West Tennessee Research Institute
      • Memphis, Tennessee, Vereinigte Staaten, 38119
        • Dr. Ramesh Gupta
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78731-3146
        • Austin Regional Clinic
      • Carrollton, Texas, Vereinigte Staaten, 75007
        • Trinity Clinical Research, LLC

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening (results either obtained during screening or documented in the participant's medical history are acceptable to fulfill these criteria for Schirmer's test, unstimulated salivary flow test, ocular staining score, or labial salivary gland biopsy), and was diagnosed with pSS no less than 26 weeks prior to screening
  • At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A [SSA])
  • Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
  • At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
  • It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccination regimen at least 2 weeks prior to study related visits or procedures. Study participants should, follow applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic glucocorticoids within the previous 12 months
  • Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
  • Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
  • Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative, are likely to interfere with the investigator's ability to assess pSS manifestations

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Group 1: Placebo

Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Placebo infusion will be administered intravenously.

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Experimental: Group 2: Nipocalimab Dose 1

Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

Andere Namen:
  • JNJ-80202135
  • M281
Experimental: Group 3: Nipocalimab Dose 2

Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

Andere Namen:
  • JNJ-80202135
  • M281

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
Zeitfenster: Baseline (Week 0), Week 24

In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.

Baseline (Week 0), Week 24

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
Zeitfenster: Baseline (Week 0), Week 24

Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Zeitfenster: Baseline (Week 0), Week 24

ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
Zeitfenster: Baseline (Week 0), Week 24

In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.

Baseline (Week 0), Week 24
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
Zeitfenster: Baseline (Week 0), Week 24

Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of >= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
Zeitfenster: At Week 24

Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of >=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of >=3 in clinESSDAI score (3), (ii) decrease of >=1 point or >=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of >=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of >=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of >=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of >=25% in rheumatoid factor/decrease of >=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).

At Week 24
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
Zeitfenster: At Week 24

DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score * domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of >= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).

At Week 24
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
Zeitfenster: At Week 24

Percentage of participants with improvement from baseline in >= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in >= 3 of the following 5 categories: (i) clinESSDAI score less than (<) 5 (low disease activity), (ii) decrease of >= 1 point or >= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (<= 5 mm) and an increase of >= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of >= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of >= 25% in rheumatoid factor or decrease of >= 10% in IgG.

At Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
Zeitfenster: Post first administration of study intervention (Week 0) up to Week 30

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
Zeitfenster: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin < 20 grams per liter (g/L) (< 2.0 grams per deciliter [g/dL]); applicable to participants who had albumin greater than (>) 20 g/L at previous assessments. Those who entered with < 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin > 20 g/L or those who entered with albumin < 20g/L and then had an increase in albumin > 20 g/L which subsequently decreased to < 20 g/L were reported as an AESI.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
Zeitfenster: Post first administration of study intervention (Week 0) up to Week 30

A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
Zeitfenster: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Zeitfenster: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (< 36 degree Celsius and > 38 degree Celsius), pulse rate (<= 50 beats per minute [bpm] and with >= 15 bpm decrease from baseline and >= 120 bpm and with >= 15 bpm increase from baseline), and blood pressure (systolic blood pressure [SBP]: <= 90 millimeters of mercury [mmHg] and with >= 20 mmHg decrease from baseline and >= 160 mmHg and with >= 20 mmHg increase from baseline; diastolic blood pressure [DBP]: <= 50 mmHg and with >= 15 mmHg decrease from baseline and >= 100 mmHg and with >= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Zeitfenster: Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Laboratory parameters included hematology (platelet count [platelets: decrease > 20% and value < 100)], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential [lymphocytes: decrease > 20% and value < 0.08], [leukocytes: decrease > 10% and value < 2.5], [neutrophils: increase > 30% and value > 0.90], [eosinophils: increase > 20% and value > 0.10]), serum chemistry (phosphate [decrease > 10% and value < 0.6), lipid panel (high-density lipoprotein [HDL] and low-density lipoprotein [LDL], creatine kinase: increase > 20% and value > 960, cholesterol: value >= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.

Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Serum Nipocalimab Concentration Over Time
Zeitfenster: Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30

Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.

Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
Change From Baseline in C-reactive Protein (CRP)
Zeitfenster: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30

Change from baseline in CRP were reported.

Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Zeitfenster: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
Zeitfenster: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
Zeitfenster: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30

Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.

Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
Zeitfenster: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in autoantibodies included RF were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
Zeitfenster: Baseline (Week 0) up to Week 30

Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
Zeitfenster: Baseline (Week 0) up to Week 30

Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

21. September 2021

Primärer Abschluss (Tatsächlich)

23. Oktober 2023

Studienabschluss (Tatsächlich)

30. November 2023

Studienanmeldedaten

Zuerst eingereicht

9. Juli 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Juli 2021

Zuerst gepostet (Tatsächlich)

20. Juli 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CR109062
  • 2021-000665-32 (EudraCT-Nummer)
  • 80202135SJS2001 (Andere Kennung: Janssen Research & Development, LLC)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .